pharma QA – Page 40 – Pharma.Tips

Biologic stability failure (real-time/accelerated) during commercial manufacturing campaign: investigation strategy aligned to FDA/EMA expectations and comparability principles

Investigating Biologic Stability Failures during Commercial Manufacturing Campaigns In the realm of pharmaceutical manufacturing, the stability of biologics is a critical component, especially during commercial campaigns. Unforeseen stability failures, whether…

Cleaning validation failure during CPV review: facility and HVAC risk mitigation

Mitigating Risks Following a Cleaning Validation Failure During CPV Review Cleaning validation failures can pose significant risks in pharmaceutical manufacturing, particularly during Continued Process Verification (CPV) reviews. This article demonstrates…

Biologic endotoxin OOS during deviation investigation board review: data integrity checks for bioassays and analytical similarity packages

Exploring Biologic Endotoxin OOS During Deviation Investigation Review: Ensuring Data Integrity The detection of out-of-specification (OOS) results for endotoxin levels in biologics can significantly disrupt pharmaceutical manufacturing processes and compliance.…

Stability degradation in hormonal manufacturing: CAPA aligned to regulatory expectations

Addressing Stability Degradation in the Manufacturing of Hormonal Products Stability degradation in hormonal manufacturing poses significant risks not just to the product quality but also to compliance with regulatory standards…

Biologic residual DNA OOS during deviation investigation board review: single-use systems risk controls, leachables review, and supplier oversight actions

Addressing Biologic Residual DNA OOS during Deviation Investigation Board Review Pharmaceutical manufacturers face stringent regulatory expectations which require a thorough and structured approach to investigating Out of Specification (OOS) results,…

Carryover contamination risk during multi-product campaign: CAPA aligned to regulatory expectations

“`html Addressing Carryover Contamination Risks in Multi-Product Campaigns: A Comprehensive CAPA Approach In the realm of pharmaceutical manufacturing, particularly within the production of hormonal products, the risk of carryover contamination…

Biologic host cell protein (HCP) OOS after single-use system supplier change: viral safety and contamination response plan with inspection-ready evidence

“`html Handling OOS Reports of Biologic Host Cell Protein (HCP) Post Single-Use System Supplier Change In the dynamic field of pharmaceutical manufacturing, particularly in biologics, deviations such as Out of…

Potency variability during multi-product campaign: facility and HVAC risk mitigation

Addressing Potency Variability in Multi-Product Campaigns: A Thorough Investigation In pharmaceutical manufacturing, potency variability can pose significant challenges, especially during multi-product campaigns. This scenario typically arises when different drug formulations…

Biologic viral clearance validation gap after upstream media/raw material change: patient safety impact assessment and batch disposition governance

Assessing Viral Clearance Validation Gaps from Upstream Media and Raw Material Changes in Biologic Manufacturing The pharmaceutical industry is no stranger to the complexities of ensuring patient safety through rigorous…

Biologic cold chain excursion impact during PPQ / process validation: investigation strategy aligned to FDA/EMA expectations and comparability principles

“`html Investigating the Impact of Cold Chain Excursions on Biologics During Process Validation In the pharmaceutical manufacturing sector, maintaining the integrity of biologics throughout the supply chain is critical, particularly…

Cleaning validation failure during CPV review: CAPA aligned to regulatory expectations

Addressing Cleaning Validation Failures During Continuous Process Verification Reviews In pharmaceutical manufacturing, ensuring compliance with cleaning validation protocols is critical to product quality and regulatory adherence. A recent cleaning validation…

Biologic subvisible particles OOS during stability pull at 3/6/12 months: investigation strategy aligned to FDA/EMA expectations and comparability principles

“`html Investigation Strategy for OOS of Biologic Subvisible Particles During Stability Pulls: Aligning with FDA/EMA Expectations Encountering out-of-specification (OOS) results for subvisible particles during stability pulls at 3, 6, and…